X
Sep 02, 2021 09:39 PM (GMT+8) · EqualOcean
Cailian news agency, September 2, Tiantan biology announced that its affiliated enterprise Wuhan blood system obtained the approval for drug clinical trial issued by the State Drug Administration and agreed to carry out the clinical trial of "intravenous injection of covid-19 human immunoglobulin (pH4)"; The raw material of this product comes from the plasma of healthy people immunized with vaccine collected by the subordinate plasma station of Wuhan blood system, and screened by antibody titer.